Mélanome uvéal et tumeurs oculaires CLXS196X2101 A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma Paris SOPHIE PIPERNO-NEUMANN
Mélanome uvéal et tumeurs oculaires IMCgp100-202 A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma Paris
Pédiatrie Neuroblastomes J1O-MC-JZHD A Phase 1 Study of;Aurora Kinase A Inhibitor LY3295668 erbumine as a Single;Agent and in Combination in Patients with;Relapsed/Refractory Neuroblastoma Paris ISABELLE AERTS
Mélanome uvéal et tumeurs oculaires PLUME A phase II, monocentric, single arm trial;evaluating the efficacy and safety of;Pembrolizumab in combination with Lenvatinib;in metastatic Uveal MElanoma patients Paris MANUEL RODRIGUES
Pédiatrie Neuroblastomes HR-NBL2 High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) Paris GUDRUN SCHLEIERMACHER
Mélanome uvéal et tumeurs oculaires SALOME / IC 2019-13 Follow-up of patients with uveal melanoma adapted to the risk of relapse. Paris SOPHIE PIPERNO-NEUMANN
Pédiatrie Neuroblastomes EUSA-PASS (EUSA-DB-0001) A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta Paris GUDRUN SCHLEIERMACHER
Pédiatrie Neuroblastomes NANT 2015-02 (IC 2018-05) Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma Paris GUDRUN SCHLEIERMACHER